Results 51 to 60 of about 178,517 (322)

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL

Blood Advances, 2022
Bruton’s tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options.
F. Awan, D. Addison, F. Alfraih, S. Baratta, R. N. Campos, M. Cugliari, Y. Goh, V. Ionin, Stefanie Mundnich, A. Sverdlov, C. Tam, L. Ysebaert   +11 more
semanticscholar   +1 more source

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

Respiratory Medicine Case Reports, 2017
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia.
Benjamin Arthurs, MD, Kathy Wunderle, MD, Maylee Hsu, MD, Suil Kim, MD, PhD   +3 more
doaj   +1 more source

Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury

Frontiers in Medicine, 2022
This study aimed to investigate the role and molecular mechanisms of Bruton's tyrosine kinase (BTK), a member of the Tec family in burn sepsis-induced intestinal injury. Eighty C57BL/6 mice were randomly divided into four groups: the sham group, the burn
Jia Wan, Xi Yu, Jia-Qi Niu, Le Qiu, Fei Wang, Xu-Lin Chen   +5 more
doaj   +1 more source

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Frontiers in Immunology, 2021
Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation ...
G. Ringheim, M. Wampole, Kinsi Oberoi
semanticscholar   +1 more source

Ibrutinib for B cell malignancies [PDF]

, 2014
Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies.
Aileen Novero, Delong Liu, George Dous, Pavan M Ravella, Yamei Chen   +4 more
core   +1 more source

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Blood Cancer Journal, 2022
Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pirtobrutinib has
Burcu Aslan, G. Kismali, LaKesla R Iles, G. Manyam, M. Ayres, Lisa S. Chen, Mihai Gagea, M. T. Bertilaccio, W. Wierda, V. Gandhi   +9 more
semanticscholar   +1 more source

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]

, 2015
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani, Bendall, Burger, Burnett, Byrd, Chung, Dasmahapatra, de Rooij, de Weers, Dohner, Dos Santos, Dubovsky, Döhner, Fiedler, Fiedler, Gao, Gu, Hahn, Honda, Horwood, Ikeda, Ito, Juliusson, Kim, Koketsu, Kvinlaug, Ma, Matsunaga, Meng, Miettinen, Oellerich, Rushworth, Rushworth, Rushworth, Rushworth, Rushworth, Schmidt, Sivina, Sun, Tai, Tomasson, Wang, Wang, Welch   +43 more
core   +1 more source

Studies of quantum mechanics/molecular docking on zanubrutinib as potential repurposed against Covid-19 [PDF]

, 2022
. Recently, Zanubrutinib, as a novel, selective covalent and potent inhibitor Bruton’s tyrosine kinase (BTK), has been used to treat COVID-19 patients. In this regard, the interaction of Zanubrutinib with Bruton’s tyrosine kinase (BTK) inhibitor studied.
Madadi Mahani , Nosrat, Zia Mohammadi , Sayed   +1 more
core   +2 more sources

BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is implicated.
Hendriks, RW, van, Loo PF
openaire   +3 more sources

Severe B Cell Deficiency in Mice Lacking the Tec Kinase Family Members Tec and Btk [PDF]

, 2000
The cytoplasmic protein tyrosine kinase Tec has been proposed to have important functions in hematopoiesis and lymphocyte signal transduction. Here we show that Tec-deficient mice developed normally and had no major phenotypic alterations of the immune ...
Baltimore, David, Ellmeier, Wilfried, Hatam, Farah, Jung, Steffen, Littman, Dan R., Mano, Hiroyuki, Sunshine, Mary Jean, Xu, Yang   +7 more
core   +3 more sources